Filing Flows › Stoke Therapeutics (STOK) › Q2 2026 › vs Q2 2025
Stoke Therapeutics (STOK) Q2 2026 vs Q2 2025 (year over year)
Stoke Therapeutics's revenue fell $4.5M (-33%) from $13.8M in Q2 2025 to $9.3M in Q2 2026.
Stoke Therapeutics, Q2 2026: revenue $9.3M (-32% year over year), operating margin -701.7%, net loss $61.6M, operating cash flow −$56.6M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $9.3M | $13.8M | −$4.5M | -33% |
| Other income, net | $3.8M | $3.8M | −$6K | -0.2% |
| Net loss | $61.6M | $23.5M | $38.1M | +162% |
| Costs & expenses | $74.8M | $41.1M | $33.6M | +82% |
| Operating costs | $74.8M | $41.1M | $33.6M | +82% |
| Research & development | $49.5M | $25.9M | $23.6M | +91% |
| SG&A | $25.3M | $15.3M | $10.0M | +65% |
| Operating cash sources | $67.8M | $33.5M | $34.4M | +103% |
| Depreciation | $458K | $446K | $12K | +3% |
| Share-based compensation | $10.8M | $7.6M | $3.2M | +42% |
| Cash used in operations | $56.6M | $25.4M | $31.2M | +123% |
| Net loss absorbed | $61.6M | $23.5M | $38.1M | +162% |
| Working capital & other | $6.2M | $10.0M | −$3.8M | -38% |
Questions
How much did Stoke Therapeutics's revenue grow year over year in Q2 2026?
Stoke Therapeutics's revenue fell $4.5M (-33%) from $13.8M in Q2 2025 to $9.3M in Q2 2026.